Back to mobile site

FBR Capital Starts Achillion Pharmaceuticals (ACHN) at Outperform, $16 PT

September 14, 2016 5:31 PM EDT Send to a Friend
FBR Capital initiates coverage on Achillion Pharmaceuticals (NASDAQ: ACHN) with a Outperform rating and a price target of $16.00.Analyst Christopher ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login